Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057107 · ClinicalTrials.gov registry record · Phase 2
SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN
A Phase 2 study, sponsored by Heath Skinner.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02057107 is a Phase 2 study that has completed, run by Heath Skinner. The registered enrollment target is 40 participants.
The verdict
NCT02057107, a Phase 2 study, has completed, sponsored by Heath Skinner.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The aim of this trial is to examine the addition of docetaxel on disease progression, metastasis and survival of patients otherwise treated with SBRT and cetuximab alone. To better resolve the impact of the experimental treatment the presence/absence of prior cetuximab treatment will be determine before assigning treatment to either cetuximab and SBRT only or cetuximab, SBRT, and docetaxel.
Interventions
- DRUG Docetaxel
- DRUG Cetuximab
- RADIATION SBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-07-03 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057107
The ClinicalTrials.gov registry entry for NCT02057107 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heath Skinner, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT02057107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057107 about?
NCT02057107 is a clinical study titled "SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN". The aim of this trial is to examine the addition of docetaxel on disease progression, metastasis and survival of patients otherwise treated with SBRT and cetuximab alone. To better resolve the impact of the experimental treatment the presence/absence of prior cetuximab treatment will be determine be...
What is the current status of trial NCT02057107?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2013-07-03. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02057107?
The interventions under investigation include: Docetaxel (DRUG), Cetuximab (DRUG), SBRT (RADIATION).
Who is sponsoring clinical trial NCT02057107?
This trial is sponsored by Heath Skinner, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.